Cannabinoid receptors in acute and chronic complications of atherosclerosis

British Journal of Pharmacology

Volumn 153, Issue 2, 2008, Pages 290-298

  Mach, F ^a   Montecucco, F ^a   Steffens, S ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Atherosclerosis; Cannabinoid receptors; Cannabinoids; Inflammation; Myocardial infarction; Post ischaemic heart failure; Remodelling; Stroke

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N MORPHOLINO 1H PYRAZOLE 3 CARBOXAMIDE; 1 DEOXY 3 (1,1 DIMETHYLBUTYL) DELTA8 TETRAHYDROCANNABINOL; 2 ARACHIDONOYLGLYCEROL; 2 LINOEOYLGLYCEROL; 2 METHYL 3 (1 NAPHTHOYL) 1 PROPYLINDOLE; 2 PALMITOYLGLYCEROL; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 4 [4 (1,1 DIMETHYLHEPTYL) 2,6 DIMETHOXYPHENYL] 6,6 DIMETHYLBICYCLO[3.1.1]HEPT 2 EN 2 YLMETHANOL; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; 6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; ANANDAMIDE; BAY 387271; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR AGONIST; CANNABINOID RECEPTOR ANTAGONIST; DEXANABINOL; DRONABINOL; GLYCEROL DERIVATIVE; RIMONABANT; UNCLASSIFIED DRUG;

ATHEROSCLEROSIS; BLOOD PRESSURE; CELL MIGRATION; CELL PROLIFERATION; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CYTOKINE RELEASE; DISEASE COURSE; DRUG INHIBITION; ENDOTHELIUM CELL; HEART FUNCTION; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART RATE; HEMORRHAGIC SHOCK; HUMAN; INFLAMMATION; LIVER INJURY; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPERFUSION INJURY; REVIEW; RISK FACTOR; UPREGULATION;

ACUTE DISEASE; ANIMALS; ATHEROSCLEROSIS; CHRONIC DISEASE; ENDOCANNABINOIDS; HUMANS; RECEPTORS, CANNABINOID;

EID: 38349093269     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0707517     Document Type: Review

References (103)

1. Abi-Younes S, Sauty A, Mach F, Sukhova GK, Libby P, Luster AD (2000). The stromal cell-derived factor-1 chemokine is a potent platelet agonist highly expressed in atherosclerotic plaques. Circ Res 86: 131-138.
2. Aguado T, Romero E, Monory K, Palazuelos J, Sendtner M, Marsicano G et al. (2007). The CB1 cannabinoid receptor mediates excitotoxicity-induced neural progenitor proliferation and neurogenesis. J Biol Chem 282: 23892-23898.
3. Ashton JC, Rahman RM, Nair SM, Sutherland BA, Glass M, Appleton I (2007). Cerebral hypoxia-ischemia and middle cerebral artery occlusion induce expression of the cannabinoid CB2 receptor in the brain. Neurosci Lett 412: 114-117.
4. Bar-Joseph A, Berkovitch Y, Adamchik J, Biegon A (1994). Neuroprotective activity of HU-211, a novel NMDA antagonist, in global ischemia in gerbils. Mol Chem Neuropathol 23: 125-135.
5. Bátkai S, Járai Z, Wagner JA, Goparaju SK, Varga K, Liu J et al. (2001). Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis. Nat Med 7: 827-832.
6. Bátkai S, Mukhopadhyay P, Harvey-White J, Kechrid R, Pacher P, Kunos G (2007a). Endocannabinoids acting at CB1 receptors mediate the cardiac contractile dysfunction in vivo in cirrhotic rats. Am J Physiol Heart Circ Physiol 293: H1689-H1695.
7. Bátkai S, Osei-Hyiaman D, Pan H, El-Assal O, Rajesh M, Mukhopadhyay P et al. (2007b). Cannabinoid-2 receptor mediates protection against hepatic ischemia/reperfusion injury. FASEB J 21: 1788-1800.
8. Bátkai S, Pacher P, Osei-Hyiaman D, Radaeva S, Liu J, Harvey-White J et al. (2004). Endocannabinoids acting at cannabinoid-1 receptors regulate cardiovascular function in hypertension. Circulation 110: 1996-2002.
9. Bátkai S, Rajesh M, Mukhopadhyay P, Haskó G, Liaudet L, Cravatt BF et al. (2007c). Decreased age-related cardiac dysfunction, myocardial nitrative stress, inflammatory gene expression and apoptosis in mice lacking fatty acid amide hydrolase. Am J Physiol Heart Circ Physiol 293: H909-H918.
10. Beaconsfield P (1974). Some cardiovascular effects of cannabis. Am Heart J 87: 143-146.
11. Berger C, Schmid PC, Schabitz WR, Wolf M, Schwab S, Schmid HH (2004). Massive accumulation of N-acylethanolamines after stroke. Cell signalling in acute cerebral ischemia? J Neurochem 88: 1159-1167.
12. Bonz A, Laser M, Küllmer S, Kniesch S, Babin-Ebell J, Popp V et al. (2003). Cannabinoids acting on CB1 receptors decrease contractile performance in human atrial muscle. J Cardiovasc Pharmacol 41: 657-664.
13. Bouchard JF, Lépicier P, Lamontagne D (2003). Contribution of endocannabinoids in the endothelial protection afforded by ischemic preconditioning in the isolated rat heart. Life Sci 72: 1859-1870.
14. Braunersreuther V, Mach F (2006). Leukocyte recruitment in atherosclerosis: potential targets for therapeutic approaches? Cell Mol Life Sci 63: 2079-2088.
15. Carrier EJ, Kearn CS, Barkmeier AJ, Breese NM, Yang W, Nithipatikom K et al. (2004). Cultured rat microglial cells synthesize the endocannabinoid 2-arachidonylglycerol, which increases proliferation via a CB2 receptor-dependent mechanism. Mol Pharmacol 65: 999-1007.
16. Coopman K, Smith LD, Wright KL, Ward SG (2007). Temporal variation in CB2R levels following T lymphocyte activation: evidence that cannabinoids modulate CXCL12-induced chemotaxis. Int Immunopharmacol 7: 360-371.
17. Crawford WJ, Merritt JC (1979). Effects of tetrahydrocannabinol on arterial and intraocular hypertension. Int J Clin Pharmacol Biopharm 17: 191-196.
18. Després JP, Golay A, Sjöström L, Rimonabant in Obesity-Lipids Study Group (2005). Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 353: 2121-2134.
19. Deusch E, Kress HG, Kraft B, Kozek-Langenecker SA (2004). The procoagulatory effects of delta-9-tetrahydrocannabinol in human platelets. Anesth Analg 99: 1127-1130, table of contents.
20. Dewey WL (1986). Cannabinoid pharmacology. Pharmacol Rev 38: 151-178.
21. Di Filippo C, Rossi F, Rossi S, D'Amico M (2004). Cannabinoid CB2 receptor activation reduces mouse myocardial ischemia-reperfusion injury: involvement of cytokine/chemokines and PMN. J Leukoc Biol 75: 453-459.
22. Formukong EA, Evans AT, Evans FJ (1989). The inhibitory effects of cannabinoids, the active constituents of Cannabis sativa L. on human and rabbit platelet aggregation. J Pharm Pharmacol 41: 705-709.
23. Fredericks AB, Benowitz NL, Savanapridi CY (1981). The cardiovascular and autonomic effects of repeated administration of delta-9-tetrahydrocannabinol to Rhesus monkeys. J Pharmacol Exp Ther 216: 247-253.
24. Galve-Roperh I, Aguado T, Palazuelos J, Guzmán M (2007). The endocannabinoid system and neurogenesis in health and disease. Neuroscientist 13: 109-114.
25. Gawaz M, Langer H, May AE (2005). Platelets in inflammation and atherogenesis. J Clin Invest 115: 3378-3384.
26. Gelfand EV, Cannon CP (2006). Rimonabant: a cannabinoid receptor type 1 blocker for management of multiple cardiometabolic risk factors. J Am Coll Cardiol 47: 1919-1926.
27. Ghosh S, Preet A, Groopman JE, Ganju RK (2006). Cannabinoid receptor CB(2) modulates the CXCL12/CXCR4-mediated chemotaxis of T lymphocytes. Mol Immunol 43: 2169-2179.
28. Glass CK, Witztum JL (2001). Atherosclerosis. The road ahead. Cell 104: 503-516.
29. Hansson GK (2005). Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352: 1685-1695.
30. Hansson GK, Libby P (2006). The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol 6: 508-519.
31. Hayakawa K, Mishima K, Nozako M, Hazekawa M, Aoyama Y, Ogata A et al. (2007). High-cholesterol feeding aggravates cerebral infarction via decreasing the CB1 receptor. Neurosci Lett 414: 183-187.
32. Hollister LE (1986). Health aspects of cannabis. Pharmacol Rev 38: 1-20.
33. Jones RT (2002). Cardiovascular system effects of marijuana. J Clin Pharmacol 42: 58S-63S.
34. Joyeux M, Arnaud C, Godin-Ribuot D, Demenge P, Lamontagne D, Ribuot C (2002). Endocannabinoids are implicated in the infarct size-reducing effect conferred by heat stress preconditioning in isolated rat hearts. Cardiovasc Res 55: 619-625.
35. Julien B, Grenard P, Teixeira-Clerc F, Van Nhieu JT, Li L, Karsak M et al. (2005). Antifibrogenic role of the cannabinoid receptor CB2 in the liver. Gastroenterology 128: 742-755.
36. Kanakis C, Pouget M, Rosen KM (1979). Lack of cardiovascular effects of delta-9-tetrahydrocannabinol in chemically denervated men. Ann Intern Med 91: 571-574.
37. Karsak M, Gaffal E, Date R, Wang-Eckhardt L, Rehnelt J, Petrosino S et al. (2007). Attenuation of allergic contact dermatitis through the endocannabinoid system. Science 316: 1494-1497.
38. Klein TW (2005). Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat Rev Immunol 5: 400-411.
39. Klein TW, Newton C, Larsen K, Lu L, Perkins I, Nong L et al. (2003). The cannabinoid system and immune modulation. J Leukoc Biol 74: 486-496.
40. Klijn CJ, Hankey GJ, American Stroke Association and European Stroke Initiative (2003). Management of acute ischaemic stroke: new guidelines from the American Stroke Association and European Stroke Initiative. Lancet Neurol 2: 698-701.
41. Kowalska MA, Ratajczak MZ, Majka M, Jin J, Kunapuli S, Brass L et al. (2000). Stromal cell-derived factor-1 and macrophage-derived chemokine: 2 chemokines that activate platelets. Blood 96: 50-57.
42. Krylatov AV, Ugdyzhekova DS, Bernatskaya NA, Maslov LN, Mekhoulam R, Pertwee RG et al. (2001). Activation of type II cannabinoid receptors improves myocardial tolerance to arrhythmogenic effects of coronary occlusion and reperfusion. Bull Exp Biol Med 131: 523-525.
43. Lagneux C, Lamontagne D (2001). Involvement of cannabinoids in the cardioprotection induced by lipopolysaccharide. Br J Pharmacol 132: 793-796.
44. Lavie G, Teichner A, Shohami E, Ovadia H, Leker RR (2001). Long term cerebroprotective effects of dexanabinol in a model of focal cerebral ischemia. Brain Res 901: 195-201.
45. Leker RR, Gai N, Mechoulam R, Ovadia H (2003). Drug-induced hypothermia reduces ischemic damage: effects of the cannabinoid HU-210. Stroke 34: 2000-2006.
46. Leker RR, Shohami E, Abramsky O, Ovadia H (1999). Dexanabinol: a novel neuroprotective drug in experimental focal cerebral ischemia. J Neurol Sci 162: 114-119.
47. Lépicier P, Bouchard JF, Lagneux C, Lamontagne D (2003). Endocannabinoids protect the rat isolated heart against ischaemia. Br J Pharmacol 139: 805-815.
48. Levy R, Schurr A, Nathan I, Dvilanski A, Livne A (1976). Impairment of ADP-induced platelet aggregation by hashish components. Thromb Haemost 36: 634-640.
49. Libby P (2002). Inflammation in atherosclerosis. Nature 420: 868-874.
50. Libby P, Aikawa M (2002). Stabilization of atherosclerotic plaques: new mechanisms and clinical targets. Nat Med 8: 1257-1262.
51. Liu J, Batkai S, Pacher P, Harvey-White J, Wagner JA, Cravatt BF et al. (2003). Lipopolysaccharide induces anandamide synthesis in macrophages via CD14/MAPK/phosphoinositide 3-kinase/NF-kappaB independently of platelet-activating factor. J Biol Chem 278: 45034-45039.
52. Lunn CA, Fine JS, Rojas-Triana A, Jackson JV, Fan X, Kung TT et al. (2006). A novel cannabinoid peripheral cannabinoid receptor-selective inverse agonist blocks leukocyte recruitment in vivo. J Pharmacol Exp Ther 316: 780-788.
53. Lusis AJ (2000). Atherosclerosis. Nature 407: 233-241.
54. Mach F (2004). Statins as immunomodulatory agents. Circulation 109: II15-II17.
55. Maresz K, Pryce G, Ponomarev ED, Marsicano G, Croxford JL, Shriver LP et al. (2007). Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells. Nat Med 13: 492-497.
56. Maslov LN, Lasukova OV, Krylatov AV, Hanus LO, Pertwee R, Ivanchuk II et al. (2006). Role of cannabinoid receptors in the regulation of cardiac contractility during ischemia/reperfusion. Bull Exp Biol Med 142: 557-561.
57. Massa F, Marsicano G, Hermann H, Cannich A, Monory K, Cravatt BF et al. (2004). The endogenous cannabinoid system protects against colonic inflammation. J Clin Invest 113: 1202-1209.
58. Mathew RJ, Wilson WH, Humphreys D, Lowe JV, Wiethe KE (1992). Middle cerebral artery velocity during upright posture after marijuana smoking. Acta Psychiatr Scand 86: 173-178.
59. Mauler F, Horváth E, De Vry J, Jäger R, Schwarz T, Sandmann S et al. (2003). BAY 38-7271: a novel highly selective and highly potent cannabinoid receptor agonist for the treatment of traumatic brain injury. CNS Drug Rev 9: 343-358.
60. Mendizábal VE, Adler-Graschinsky E (2007). Cannabinoids as therapeutic agents in cardiovascular disease: a tale of passions and illusions. Br J Pharmacol 151: 427-440.
61. Mittleman MA, Lewis RA, Maclure M, Sherwood JB, Muller JE (2001). Triggering myocardial infarction by marijuana. Circulation 103: 2805-2809.
62. Mukhopadhyay P, Bátkai S, Rajesh M, Czifra N, Harvey-White J, Haskó G et al. (2007). Pharmacological inhibition of CB1 cannabinoid receptor protects against doxorubicin-induced cardiotoxicity. J Am Coll Cardiol 50: 528-536.
63. Murray CJ, Lopez AD (1997). Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet 349: 1269-1276.
64. Muthian S, Rademacher DJ, Roelke CT, Gross GJ, Hillard CJ (2004). Anandamide content is increased and CB1 cannabinoid receptor blockade is protective during transient, focal cerebral ischemia. Neuroscience 129: 743-750.
65. Nagayama T, Sinor AD, Simon RP, Chen J, Graham SH, Jin K et al. (1999). Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures. J Neurosci 19: 2987-2995.
66. Nakajima Y, Furuichi Y, Biswas KK, Hashiguchi T, Kawahara K, Yamaji K et al. (2006). Endocannabinoid, anandamide in gingival tissue regulates the periodontal inflammation through NF-kappaB pathway inhibition. FEBS Lett 580: 613-619.
67. Nelken NA, Coughlin SR, Gordon D, Wilcox JN (1991). Monocyte chemoattractant protein-1 in human atheromatous plaques. J Clin Invest 88: 1121-1127.
68. Newby AC (2005). Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture. Physiol Rev 85: 1-31.
69. Ni X, Geller EB, Eppihimer MJ, Eisenstein TK, Adler MW, Tuma RF (2004). Win 55212-2, a cannabinoid receptor agonist, attenuates leukocyte/endothelial interactions in an experimental autoimmune encephalomyelitis model. Mult Scler 10: 158-164.
70. Nieswandt B, Aktas B, Moers A, Sachs UJ (2005). Platelets in atherothrombosis: lessons from mouse models. J Thromb Haemost 3: 1725-1736.
71. Osterud B, Bjorklid E (2003). Role of monocytes in atherogenesis. Physiol Rev 83: 1069-1112.
72. Pacher P, Bátkai S, Kunos G (2005a). Blood pressure regulation by endocannabinoids and their receptors. Neuropharmacology 48: 1130-1138.
73. Pacher P, Bátkai S, Kunos G (2005b). Cardiovascular pharmacology of cannabinoids. Handb Exp Pharmacol 168: 599-625.
74. Pacher P, Bátkai S, Kunos G (2006). The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 58: 389-462.
75. Pacher P, Bátkai S, Osei-Hyiaman D, Offertáler L, Liu J, Harvey-White J et al. (2005c). Hemodynamic profile, responsiveness to anandamide, and baroreflex sensitivity of mice lacking fatty acid amide hydrolase. Am J Physiol Heart Circ Physiol 289: H533-H541.
76. Panikashvili D, Mechoulam R, Beni SM, Alexandrovich A, Shohami E (2005). CB1 cannabinoid receptors are involved in neuroprotection via NF-kappa B inhibition. J Cereb Blood Flow Metab 25: 477-484.
77. Panikashvili D, Simeonidou C, Ben-Shabat S, Hanus L, Breuer A, Mechoulam R et al. (2001). An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature 413: 527-531.
78. Parmentier-Batteur S, Jin K, Mao XO, Xie L, Greenberg DA (2002). Increased severity of stroke in CB1 cannabinoid receptor knockout mice. J Neurosci 22: 9771-9775.
79. Pinto A, Tuttolomondo A, Di Raimondo D, Fernandez P, Licata G (2004). Cerebrovascular risk factors and clinical classification of strokes. Semin Vasc Med 4: 287-303.
80. Rajesh M, Mukhopadhyay P, Bátkai S, Haskó G, Liaudet L, Drel VR et al. (2007a). Cannabidiol attenuates high glucose-induced endothelial cell inflammatory response and barrier disruption. Am J Physiol Heart Circ Physiol 293: H610-H619.
81. Rajesh M, Mukhopadhyay P, Batkai S, Hasko G, Liaudet L, Huffman JW et al. (2007b). Cannabinoid-2 receptor stimulation attenuates TNF{alpha}-induced human endothelial cell activation, transendothelial migration of monocytes, and monocyte-endothelial adhesion. Am J Physiol Heart Circ Physiol 293: 2210-2218.
82. Rajesh M, Pan H, Mukhopadhyay P, Bátkai S, Osei-Hyiaman D, Haskó G et al. (2007c). Pivotal Advance: cannabinoid-2 receptor agonist HU-308 protects against hepatic ischemia/reperfusion injury by attenuating oxidative stress, inflammatory response, and apoptosis. J Leukoc Biol 82:(in press).
83. Sacerdote P, Martucci C, Vaccani A, Bariselli F, Panerai AE, Colombo A et al. (2005). The nonpsychoactive component of marijuana cannabidiol modulates chemotaxis and IL-10 and IL-12 production of murine macrophages both in vivo and in vitro. J Neuroimmunol 159: 97-105.
84. Sacerdote P, Massi P, Panerai AE, Parolaro D (2000). In vivo and in vitro treatment with the synthetic cannabinoid CP55, 940 decreases the in vitro migration of macrophages in the rat: involvement of both CB1 and CB2 receptors. J Neuroimmunol 109: 155-163.
85. Schecter AD, Calderon TM, Berman AB, McManus CM, Fallon JT, Rossikhina M et al. (2000). Human vascular smooth muscle cells possess functional CCR5. J Biol Chem 275: 5466-5471.
86. Scheuerer B, Ernst M, Dürrbaum-Landmann I, Fleischer J, Grage-Griebenow E, Brandt E et al. (2000). The CXC-chemokine platelet factor 4 promotes monocyte survival and induces monocyte differentiation into macrophages. Blood 95: 1158-1166.
87. Sidney S (2002). Cardiovascular consequences of marijuana use. J Clin Pharmacol 42: 64S-70S.
88. Sinor AD, Irvin SM, Greenberg DA (2000). Endocannabinoids protect cerebral cortical neurons from in vitro ischemia in rats. Neurosci Lett 278: 157-160.
89. Sommer C, Schomacher M, Berger C, Kuhnert K, Müller HD, Schwab S et al. (2006). Neuroprotective cannabinoid receptor antagonist SR141716A prevents downregulation of excitotoxic NMDA receptors in the ischemic penumbra. Acta Neuropathol (Berlin) 112: 277-286.
90. Steffens S, Veillard NR, Arnaud C, Pelli G, Burger F, Staub C et al. (2005). Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice. Nature 434: 782-786.
91. Teixeira-Clerc F, Julien B, Grenard P, Tran Van Nhieu J, Deveaux V, Li L et al. (2006). CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis. Nat Med 12: 671-676.
92. Underdown NJ, Hiley CR, Ford WR (2005). Anandamide reduces infarct size in rat isolated hearts subjected to ischaemia-reperfusion by a novel cannabinoid mechanism. Br J Pharmacol 146: 809-816.
93. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rössner S, RIO-Europe Study Group AN (2005). Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 365: 1389-1397.
94. Varga K, Wagner JA, Bridgen DT, Kunos G (1998). Platelet- and macrophage-derived endogenous cannabinoids are involved in endotoxin-induced hypotension. FASEB J 12: 1035-1044.
95. Veillard NR, Steffens S, Burger F, Pelli G, Mach F (2004). Differential expression patterns of proinflammatory and antiinflammatory mediators during atherogenesis in mice. Arterioscler Thromb Vasc Biol 24: 2339-2344.
96. von Hundelshausen P, Weber KS, Huo Y, Proudfoot AE, Nelson PJ, Ley K et al. (2001). RANTES deposition by platelets triggers monocyte arrest on inflamed and atherosclerotic endothelium. Circulation 103: 1772-1777.
97. Wagner JA, Hu K, Karcher J, Bauersachs J, Schäfer A, Laser M et al. (2003). CB(1) cannabinoid receptor antagonism promotes remodeling and cannabinoid treatment prevents endothelial dysfunction and hypotension in rats with myocardial infarction. Br J Pharmacol 138: 1251-1258.
98. Wagner JA, Varga K, Ellis EF, Rzigalinski BA, Martin BR, Kunos G (1997). Activation of peripheral CB1 cannabinoid receptors in haemorrhagic shock. Nature 390: 518-521.
99. Wang Y, Liu Y, Ito Y, Hashiguchi T, Kitajima I, Yamakuchi M et al. (2001). Simultaneous measurement of anandamide and 2-arachidonoylglycerol by polymyxin B-selective adsorption and subsequent high-performance liquid chromatography analysis: increase in endogenous cannabinoids in the sera of patients with endotoxic shock. Anal Biochem 294: 73-82.
100. Weber C (2005). Platelets and chemokines in atherosclerosis: partners in crime. Circ Res 96: 612-616.
101. Weber C, Schober A, Zernecke A (2004). Chemokines: key regulators of mononuclear cell recruitment in atherosclerotic vascular disease. Arterioscler Thromb Vasc Biol 24: 1997-2008.
102. Ylä-Herttuala S, Lipton BA, Rosenfeld ME, Särkioja T, Yoshimura T, Leonard EJ et al. (1991). Expression of monocyte chemoattractant protein 1 in macrophage-rich areas of human and rabbit atherosclerotic lesions. Proc Natl Acad Sci USA 88: 5252-5256.
103. Yu X, Dluz S, Graves DT, Zhang L, Antoniades HN, Hollander W et al. (1992). Elevated expression of monocyte chemoattractant protein 1 by vascular smooth muscle cells in hypercholesterolemic primates. Proc Natl Acad Sci USA 89: 6953-6957.